The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $218,370.00 firm fixed-price delivery order contract to Mayo Clinic, a large non-profit academic medical center, for "Pharmacokinetic Studies with Selected Anticancer Compounds in NSG Mice." The period of performance is September 13, 2019 through September 12, 2024. This delivery order is issued under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients...
This is a firm-fixed price delivery order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Mayo Clinic, a renowned non-profit academic medical center. The contract is for $1,603.00 and covers pre-clinical pharmacokinetic and pharmacology evaluations of cancer therapeutic agents being developed under the NCI's Experimental Therapeutics program. This work supports the transition of promising cancer treatments from the laboratory to early...
This is a delivery order awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Mayo Clinic, a large non-profit academic medical center. The five-year, $204,622.95 contract supports pharmacokinetic and bioavailability studies of selected anticancer compounds in mice, which will provide analytical support to the NCI's Experimental Therapeutics program. Mayo Clinic is conducting these preclinical evaluations under a larger $9.9 million...
Mayo Clinic was awarded a cost-plus-fixed-fee delivery order against its indefinite delivery/indefinite quantity contract with the National Cancer Institute. The $1,996,069 order has a period of performance through July 2023 to support preclinical pharmacokinetic evaluations for the National Cancer Institute's Experimental Therapeutics program in Rochester, Minnesota. No set-aside designation was used for this order to further the agency's aim of aiding the development and approval of new cancer...
This federal contract award, valued at $1,070.00, was issued by the National Cancer Institute (NCI) to Mayo Clinic, a renowned non-profit academic medical center, to provide contract orientation and kick-off meeting support for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract titled "Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients." The contract is structured as a firm-fixed price delivery order and does not have a...
This is a definitive contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Mayo Clinic, a renowned non-profit academic medical center. The $39,597,204.00 contract is for early-stage therapeutic development with a Phase II emphasis. The contract does not have a set-aside designation. Under this contract, Mayo Clinic will provide research and development services to support preclinical pharmacokinetic and pharmacology evaluations of...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a delivery order contract worth $3,665,424.78 to the Mayo Clinic, a large non-profit academic medical center focused on integrated clinical practice, education, and research. The contract is to provide core infrastructure support for the Cancer Prevention Agent Development Program's Early Phase Clinical Research efforts. This award is not a set-aside contract. Mayo Clinic has extensive...
The National Cancer Institute (NCI) awarded a $1,956,302.92 cost-no-fee delivery order contract to Mayo Clinic for core infrastructure support for the Cancer Prevention Agent Development Program. This contract supports the NCI's Experimental Therapeutics program, enabling Mayo Clinic to conduct preclinical pharmacokinetic and pharmacology evaluations of cancer therapeutic agents from lead selection through early clinical trials. The contract has a performance period through September 2023 and is...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a delivery order contract to Mayo Clinic, a large non-profit academic medical center, to provide core infrastructure support services. The $658,179.00 contract does not have a set-aside designation and is part of the Cancer Prevention Agent Development Program: Early Phase Clinical Research major program. Mayo Clinic will implement bioanalytical methods, conduct pharmacokinetic...
This federal contract award, valued at $259,490.16, was issued by the National Cancer Institute (NCI) to Mayo Clinic, a renowned non-profit academic medical center. The contract provides "Core Infrastructure Support" and is classified as a Delivery Order with a Cost No Fee pricing type. The award does not have a set-aside designation. Mayo Clinic holds a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the NCI, valued at up to $9.9 million, to provide...
Mayo Clinic is providing research and development services as the prime contractor on a $167,149.99 delivery order against the National Cancer Institute's Pharmacokinetic and Pharmacology Evaluations for Cancer Patients indefinite delivery contract. This order is for Milestone 3 of preclinical pharmacokinetic studies with selected anticancer compounds in mice, including pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients. The goal is to aid development and potential U.S. Food and Drug Administration approval of new treatments by quantifying compounds in biological samples from animal studies. The completion date for these services to the National Institutes of Health's National Cancer Institute is June 30, 2021. No set-aside provision was specified for this award.